Evidence map›Paper›PMID 40581685›Full record

ArticleNPJ precision oncology2025

Explainable, federated deep learning model predicts disease progression risk of cutaneous squamous cell carcinoma.

Juan I Pisula, Doris Helbig, Lucas Sancéré, Oana-Diana Persa, Corinna Bürger, Anne Fröhlich, Carina Lorenz, Sandra Bingmann, Dennis Niebel, Konstantin Drexler and 4 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Juan I Pisula *Institute for Biomedical Informatics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Köln, Germany.
Doris Helbig *Department for Dermatology, University Hospital Cologne, Cologne, Germany.
Lucas SancéréInstitute for Biomedical Informatics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Köln, Germany.
Oana-Diana PersaDepartment of Dermatology, Technical University Munich, Munich, Germany.
Corinna BürgerCenter for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Köln, Germany.
Anne FröhlichDepartment of Dermatology and Allergology, University Hospital Bonn, Bonn, Germany.
Carina LorenzCenter for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Köln, Germany.
Sandra BingmannDepartment for Dermatology, University Hospital Cologne, Cologne, Germany.
Dennis NiebelDepartment of Dermatology, University Medical Center Regensburg, Regensburg, Germany.
Konstantin DrexlerDepartment of Dermatology, University Medical Center Regensburg, Regensburg, Germany.
Jennifer LandsbergDepartment of Dermatology and Allergology, University Hospital Bonn, Bonn, Germany.
Roman ThomasUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Katarzyna BozekInstitute for Biomedical Informatics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Köln, Germany.
Johannes BrägelmannCenter for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Köln, Germany. johannes.braegelmann@uni-koeln.de.

Funding

Bundesministerium für Bildung und Forschung 01ZX1917BDeutsche Forschungsgemeinschaft CRC1399, project ID 413326622Deutsche Krebshilfe 70113307Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen NW21-062B
6 · The paper itself

Abstract

Predicting cancer patient disease progression is a key step towards personalized medicine and secondary prevention. Risk stratification systems based on clinico-pathological criteria aim to identify high-risk patients, but accurate predictions remain challenging. Deep learning models present new opportunities for patient risk prediction, yet their interpretability has been largely unexplored. We developed a transformer-based approach for predicting progression of cutaneous squamous cell carcinoma (cSCC) patients based on diagnostic histopathology tumor slides. Our initial model showed AUROC = 0.92 on a held-out test set, with average AUROC of 0.65 on external validation cohorts. To further increase generalizability and reduce potential privacy concerns, we trained the model in a federated manner across three clinical centers, reaching AUROC = 0.82 across all cohorts, with image-based risk scores achieving hazard ratios up to 7.42 (p < 0.01) in multivariable analyses. Through interpretability analysis, we identified spatial and morphological features predictive of progression, suggesting that tumor boundary information and tissue heterogeneity characterize progressive cSCCs. Trained exclusively on routine diagnostic slides and offering biological insights, our model can improve secondary prevention and understanding of cSCC while enabling deployment across clinical centers without administrative overheads or privacy concerns.

Identifiers

PMID40581685
PMCPMC12206231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.